Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
US10436787B2 · kind B2 · utility
0Cited by
2References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 24, 2014 |
| Grant date | Oct 8, 2019 |
| Priority date | — |
| Expiry date | Nov 24, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention is in the technical field of breast cancer management, and more particularly relates to the diagnosis of breast cancer. The invention is more particularly based on the finding that specific biomarkers (olfactomedin-4, neudesin and desmoplakin) are abberantly expressed in the blood of breast cancer patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.